Join our community of smart investors

Bioventix bullish on R&D prospects

The shares are down 13 per cent across the year, but this is potentially out of step with the company’s earning potential
October 31, 2023
  • Revenue and profit progress
  • Siemens partnership underpins growth

Monoclonal antibodies, or clones of a single antibody, are a key component of many clinical diagnostic tests. Surrey-based Bioventix (BVXP) is a supplier of sheep monoclonal antibodies (SMAs) for use in a variety of human blood tests around the world. It might sound like a niche line of work, but the company saw progress across the year to the end of June in a way that many other biotechs did not.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in